This article is about people who invest in companies that sell marijuana. These investors are more interested in how much money these companies can make in the long run, rather than how much they make right now. They believe that these companies will grow a lot and become very valuable in the future. The value of these companies has gone up by 39% in one year. Read from source...

- The article is misleading by presenting a selective and skewed view of the cannabis sector performance. It only focuses on 14 major MSOs, ignoring other players in the industry that may have different growth prospects, risks, and valuations.
- The article uses outdated or unreliable data sources, such as Viridian Cannabis Deal Tracker, which may not capture the recent trends, challenges, or opportunities in the cannabis market. A more comprehensive and updated analysis should be conducted to provide a better understanding of the current situation and future outlook.
- The article makes sweeping generalizations and assumptions about the investors' preferences and expectations, without providing any evidence or context to support them. It also fails to acknowledge the diversity of opinions, strategies, and motivations among cannabis investors, which may vary depending on their risk appetite, time horizon, and market position.
- The article relies heavily on the concept of "market value" as a proxy for the industry's attractiveness and potential, without explaining how it is calculated, what factors influence it, or how it relates to other performance metrics, such as revenues, profits, cash flow, or asset value. It also does not consider the impact of external factors, such as regulations, competition, taxes, or consumer demand, on the market value and its fluctuations.
- The article uses emotional language and tone, such as "bet big", "risk", "growth", "rise", to appeal to the readers' emotions and create a sense of urgency, without providing any solid facts or analysis to back up these claims. It also uses vague terms, such as "long-term", "short-term", "valuation multiples", without defining them clearly or explaining how they are relevant for the cannabis investors and the industry's performance.